CLINICAL TRIALS PROFILE FOR RYBELSUS

505(b)(2) Clinical Trials for RYBELSUS

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT06083675 ↗	Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes	Withdrawn	Novo Nordisk A/S	Phase 3	2024-01-26	This study compares the medicines semaglutide with empagliflozin or metformin in people with newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood sugar and body weight are controlled when they are taking the study medicines. Participants will either get semaglutide tablets, empagliflozin tablets or metformin tablets. Which treatment participants will get is decided by chance. Currently, doses of 3 milligram (mg), 7 mg and 14 mg semaglutide tablets (Rybelsus) can be prescribed in some countries. 25 mg and 50 mg semaglutide tablets are new doses. 10 mg and 25 mg empagliflozin tablets (Jardiance) can be prescribed in some countries. 500 mg metformin tablets (STADA) can be prescribed in some countries. Participants will get 1 to 4 tablets per day for 104 weeks. The study will last for about 2 years and 7 weeks (111 weeks). Participants should not have been treated for weight management 90 days before screening or never been treated with any medicine for type 2 diabetes (except diabetes during pregnancy) before screening. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

All Clinical Trials for RYBELSUS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04707469 ↗	Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes	Recruiting	Novo Nordisk A/S	Phase 3	2021-01-15	This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot take part if they are pregnant, breast-feeding or planning to become pregnant during the study period. Women who can get pregnant will be checked for pregnancy via urine tests. Once daily semaglutide tablets (3 mg, 7 mg and 14 mg) are approved for the treatment of type 2 diabetes in the US, in the EU and in some other countries, under the brand name Rybelsus®.
NCT05035082 ↗	A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)	Recruiting	Novo Nordisk A/S	Phase 4	2021-09-01	This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the study is to see how well RYBELSUS® is at lowering blood sugar compared to other tablets when used in addition to metformin. Participants doctor will give participants either RYBELSUS® or any other blood sugar lowering tablets - which treatment participants get is decided by chance. The doctor treating participants diabetes will give participants a prescription for the medicine and tell how to take it. The study will last for about 2 years. Participants will have 3 planned visits with their doctor which are part of the usual routine diabetes management: the first visit is when participants are included in the study, the second visit is a 1-year follow-up visit, and the last visit is a 2-year follow-up visit. In addition, the study personnel will contact participants up to 3 times per year during this period and to follow-up on information from participant doctors visits. Participant will be asked to respond 3 times to 4 questionnaires via their personal smartphone or tablet or paper if participant do not have access to one during the study. All clinic visits are part of the usual routine diabetes management and are covered by participants health insurance plan. The study team will collect information from these visits recorded in the medical chart. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
NCT05147896 ↗	Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients	Not yet recruiting	University of Palermo	N/A	2021-12-01	Diabetes is a chronic disease characterized by chronic hyperglycaemia, causing microvascular and macrovascular complications. The latter lead to various disabilities: blindness, end-stage renal failure, nerve damage, formation of leg ulcers, and atherosclerosis. In people with type 2 diabetes, the probability of these atherosclerosis associated complications is twice as high as in people without diabetes. Cardiovascular diseases are also the main cause of mortality in people with diabetes. Preventive measures are therefore crucial. In people with type 2 diabetes, in addition to good glycaemic control, the choice of antidiabetic drugs is also important. Large-scale research has shown that certain glucagon-like peptide (GLP-1) receptor agonists, in addition to improving the regulation of diabetes, also have a significant effect on reducing the macrovascular complications. It is now possible to use semaglutide, a GLP-1 receptor agonist, in the tablet form. Semaglutide lowers blood sugar only when the blood sugar value rises, due to food in the digestive tract, Thus, not increasing the risk of hypoglycaemia. In addition, semaglutide has a significant effect on weight loss and very beneficial, protective effects on the cardiovascular system. Large studies have shown that in its injectable form, it significantly reduces the incidence of cardiovascular death in patients with type 2 diabetes. Therefore, the aim of the present study is to examine how semaglutide provides protective effects on the cardiovascular system and reduces the risk of diabetes type 2 associated complications. The present study will include 100 people with type 2 diabetes and last for 12 months. The subjects will receive a semaglutide oral tablet daily in addition to their current treatment (combination of metformin and a sulphonyl urea). At the beginning of the study, after 6 months and at the end of the study (after 12 months of treatment), a detailed clinical examination will be performed and blood will be taken for laboratory parameters. In addition to basic blood tests, inflammatory and oxidative stress parameters, as well as lipid fractions parameters will also be assessed. Ultrasound examination of the changes in the carotid arteries and measures of additional properties of the arteries will also be performed. The confidentiality of the data of the participants in the research will be ensured, as the data obtained during the investigation will be encrypted before processing.
NCT05147896 ↗	Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients	Not yet recruiting	University Medical Centre Ljubljana	N/A	2021-12-01	Diabetes is a chronic disease characterized by chronic hyperglycaemia, causing microvascular and macrovascular complications. The latter lead to various disabilities: blindness, end-stage renal failure, nerve damage, formation of leg ulcers, and atherosclerosis. In people with type 2 diabetes, the probability of these atherosclerosis associated complications is twice as high as in people without diabetes. Cardiovascular diseases are also the main cause of mortality in people with diabetes. Preventive measures are therefore crucial. In people with type 2 diabetes, in addition to good glycaemic control, the choice of antidiabetic drugs is also important. Large-scale research has shown that certain glucagon-like peptide (GLP-1) receptor agonists, in addition to improving the regulation of diabetes, also have a significant effect on reducing the macrovascular complications. It is now possible to use semaglutide, a GLP-1 receptor agonist, in the tablet form. Semaglutide lowers blood sugar only when the blood sugar value rises, due to food in the digestive tract, Thus, not increasing the risk of hypoglycaemia. In addition, semaglutide has a significant effect on weight loss and very beneficial, protective effects on the cardiovascular system. Large studies have shown that in its injectable form, it significantly reduces the incidence of cardiovascular death in patients with type 2 diabetes. Therefore, the aim of the present study is to examine how semaglutide provides protective effects on the cardiovascular system and reduces the risk of diabetes type 2 associated complications. The present study will include 100 people with type 2 diabetes and last for 12 months. The subjects will receive a semaglutide oral tablet daily in addition to their current treatment (combination of metformin and a sulphonyl urea). At the beginning of the study, after 6 months and at the end of the study (after 12 months of treatment), a detailed clinical examination will be performed and blood will be taken for laboratory parameters. In addition to basic blood tests, inflammatory and oxidative stress parameters, as well as lipid fractions parameters will also be assessed. Ultrasound examination of the changes in the carotid arteries and measures of additional properties of the arteries will also be performed. The confidentiality of the data of the participants in the research will be ensured, as the data obtained during the investigation will be encrypted before processing.

Clinical Trial Conditions for RYBELSUS

Condition Name

Condition Name for RYBELSUS
Intervention	Trials
Diabetes Mellitus, Type 2	5
Obesity	2
Alcohol Use Disorder	2
Cardiovascular Diseases	1

Condition MeSH

Condition MeSH for RYBELSUS
Intervention	Trials
Diabetes Mellitus, Type 2	6
Diabetes Mellitus	6
Glucose Intolerance	2
Alcoholism	2

Clinical Trial Locations for RYBELSUS

Trials by Country

Trials by Country for RYBELSUS
Location	Trials
United States	43
India	25
Australia	8
Poland	7
Canada	4

Trials by US State

Trials by US State for RYBELSUS
Location	Trials
Texas	4
Massachusetts	2
Maryland	2
Illinois	2
Georgia	2

Clinical Trial Progress for RYBELSUS

Clinical Trial Phase

Clinical Trial Phase for RYBELSUS
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	2
PHASE1	3

Clinical Trial Status

Clinical Trial Status for RYBELSUS
Clinical Trial Phase	Trials
RECRUITING	7
Not yet recruiting	4
NOT_YET_RECRUITING	2

Clinical Trial Sponsors for RYBELSUS

Sponsor Name

Sponsor Name for RYBELSUS
Sponsor	Trials
Novo Nordisk A/S	4
Pfizer	1
Herlev Hospital	1

Sponsor Type

Sponsor Type for RYBELSUS
Sponsor	Trials
Other	13
Industry	6
NIH	2

Rybelsus (oral semaglutide) clinical trials update, market analysis, and launch-to-loss-of-exclusivity projection

Last updated: July 28, 2026

Rybelsus is the first oral GLP-1 receptor agonist approved for type 2 diabetes and a key asset in Novo Nordisk’s cardiovascular risk strategy and obesity-adjacent pipeline. Near-term growth is driven by dose escalation, expanding payor coverage, and ongoing outcomes evidence in earlier intervention settings. The exclusivity picture is multi-layered: composition-of-matter, method-of-use, and formulation patents extend beyond basic platform timelines, while FDA switching and competitor entrants raise post-launch competitive pressure.

---

What is the latest clinical trials update for Rybelsus (oral semaglutide)?

Fast answer: Current clinical activity centers on outcomes expansion (CV and renal), earlier and broader-risk populations, and durability of weight-loss and glycemic control with oral dosing. Trial readouts are also positioned to support label expansions tied to the diabetes-to-obesity overlap.

Which Rybelsus trials matter most for label-expansion risk-benefit?

Key evidence base and ongoing themes for oral semaglutide include:

• Cardiovascular outcomes in type 2 diabetes
  • Oral semaglutide has demonstrated cardiovascular risk reduction in large outcomes programs that support cardiometabolic positioning.
• Renal outcomes
  • Ongoing/expanded analyses and follow-on studies track albuminuria, eGFR decline, and renal composite endpoints.
• Earlier intervention and “high risk without established ASCVD”
  • Studies test whether glycemic and weight effects translate into improved event rates in lower baseline ASCVD risk categories.
• Weight management and dose strategy
  • Oral semaglutide trials inform obesity and weight-related indications (directly or via evidence generation that can support future claims).
• Durability, adherence, and adherence to oral dosing
  • Sub-studies evaluate real-world adherence proxies and switching behavior in chronic therapy.

What is the practical trial landscape for Rybelsus right now?

Rybelsus program execution is typically measured by:

• Event-driven outcomes completion timelines for CV/renal composites (primary readouts drive payor confidence).
• Dose-finding and headroom in glycemic control for earlier lines of therapy.
• Weight and metabolic endpoint durability to improve long-term adherence and reduce discontinuation.

Key endpoints stakeholders will watch

• MACE (major adverse cardiovascular events) composites for broad label credibility in CV risk.
• Renal composites (new/worsening nephropathy endpoints).
• Weight and BMI responder thresholds to strengthen the obesity-treatment adjacency story.
• Hypoglycemia rates and tolerability for oral GLP-1 adherence.

Clinical impact implication: label expansions tied to CV and renal outcomes generally increase eligible patient populations and improve formulary access.

---

How does Rybelsus clinical efficacy compare with Ozempic, Wegovy, and other GLP-1s?

Fast answer: Efficacy benchmarks remain best-in-class among oral GLP-1 options, with clinical positioning enhanced by cardiovascular outcomes evidence. Head-to-head certainty is limited because outcomes trials differ by population, endpoint definitions, and comparator standards of care.

Oral semaglutide vs injectable semaglutide

• Mechanism equivalence: same active ingredient semaglutide, different administration route.
• Oral adherence: efficacy depends on dosing conditions (fasting, water intake timing). Trials and real-world data focus on adherence and discontinuation drivers.

Rybelsus vs other oral GLP-1 competitors

• Oral GLP-1s compete on:
  • Dose escalation convenience
  • GI tolerability profile
  • Access and payer preference for outcomes-labeled therapies

Where Rybelsus sits versus tirzepatide

• Efficacy gradients: incretin combinations (dual GIP/GLP-1) often produce larger average weight loss but differ in tolerability and access.
• Strategic positioning: Rybelsus leans on oral administration and outcomes-driven diabetes/CV positioning.

---

What patents protect Rybelsus and how strong is the patent estate for oral semaglutide?

Fast answer: The Rybelsus patent estate is layered across composition-of-matter, formulation and delivery system patents (including oral absorption-related formulation claims), and method-of-use claims tied to diabetes and related outcomes.

What patent categories typically cover Rybelsus?

• Composition-of-matter for semaglutide and relevant forms.
• Oral formulation patents
  • Claims covering tablets, absorption-promoting elements, and manufacturing attributes.
• Method-of-use patents
  • Dosing regimens and therapeutic uses for glycemic control.
  • Cardiovascular or renal risk reduction claims can be supported by outcomes data.

How does the estate affect generic or biosimilar timelines?

• Oral formulation and dosing method patents can delay:
  • Bioequivalence-based generic approvals if claims block “use” or “formulation” practice.
  • Paragraph IV settlements by extending risk windows.

---

When does Rybelsus lose exclusivity and what is the Orange Book status?

Fast answer: Loss-of-exclusivity for Rybelsus is not a single date. It is driven by the latest expiring patent family plus potential regulatory exclusivity and any pediatric exclusivity term, layered against Orange Book-listed patents.

How to model exclusivity loss in practice

Exclusivity risk is typically assessed as:

1. Latest composition-of-matter expiration that a challenger must navigate.
2. Later-expiring formulation patents that block direct product copying.
3. Later-expiring method-of-use patents that limit “label-matched” generic substitution.

Orange Book-driven entry scenarios

• If a generic files under Paragraph IV:
  • Litigation may trigger a stay.
  • Settlement can shift entry to a later date than the earliest patent expiration.

(This analysis framework applies to Rybelsus because its protection is generally multi-layered, though exact Orange Book listed numbers and dates must be pulled from FDA records for a definitive calendar.)

---

What Paragraph IV challenges and generic entry risks exist for Rybelsus?

Fast answer: Entry risk is primarily shaped by the number of Orange Book patents listed per NDA and whether any claims are judged non-infringed or invalid early enough to enable approval without settlement.

Generic entry triggers that change timelines

• High-risk patents: formulation and method-of-use claims often produce higher litigation stakes.
• Settlement structure: market share protection for Novo Nordisk frequently converts litigation into an agreed launch date for challengers.
• Label carve-outs: generics may attempt narrower dosing or indications to avoid method-of-use infringement.

---

What Rybelsus litigation affects generic timing and settlement agreements?

Fast answer: Litigation typically determines whether generic manufacturers can launch at first possible statutory approval or whether the parties reach settlements that delay launch.

What settlement terms usually matter to market projection

• Agreed launch date
• Scope of claims waived (what dosage strengths and indications can be sold)
• Design-around constraints (formulation and dosing specifics)

---

What is the commercial market analysis for Rybelsus (sales, share, and growth drivers)?

Fast answer: Rybelsus is positioned as an oral alternative to injectable incretin therapies with scaling demand driven by:

• diabetes expansion,
• adherence to chronic oral dosing,
• and payer support for CV/renal benefit rationale.

Demand drivers

• Dose escalation to higher strengths increases treated AUC and improves HbA1c outcomes, supporting retention.
• Earlier-line prescribing in type 2 diabetes increases total addressed patient pool.
• Real-world tolerability management influences persistence and switching rates.

Competitive pressures

• Injectable semaglutide demand is competed by:
  • oral/injectable GLP-1s,
  • dual incretin products,
  • and payer tiering strategies that reduce access for certain agents.

Key market metrics to track

• Script growth and persistence (12- and 24-month retention).
• Formulary coverage breadth (commercial vs Medicare Part D vs Medicaid).
• Gross-to-net pressure from rebates and copay support.
• Treatment migration to higher efficacy agents within the class.

---

What is the revenue and volume projection for Rybelsus over the next 5–10 years?

Fast answer: A base-case projection assumes continued growth through label reinforcement and persistence, followed by a deceleration phase as competitors consolidate share and as exclusivity barriers eventually allow generics or authorized competitors. Timing depends on the latest patent expirations and any settlements affecting launch dates.

Projection model structure

A typical 5–10-year model uses:

• Treated population growth (incident patients and line-of-therapy migration)
• Mean daily dose and persistence-adjusted intensity
• Price realization net of rebates
• Competitive share shifts triggered by payer preference changes

Scenario framework

• Base case: continued expansion from outcomes-led prescribing plus dose optimization; moderate deceleration as class competition intensifies.
• Upside: faster CV/renal label adoption and better persistence, plus favorable formulary breadth.
• Downside: accelerated share loss to dual incretin products, or steeper gross-to-net compression.

(A calendar-precise forecast requires current annual sales, regional breakdown, and patent/Orange Book dates; without those inputs, the projection must remain scenario-structured rather than dollar-calibrated.)

---

What manufacturing and IP barriers block generic Rybelsus oral tablets?

Fast answer: The primary barriers are formulation-specific claims and the practical difficulty of matching oral semaglutide exposure profiles under required fasting and dosing conditions.

Formulation and performance risks for generic challengers

• Bioavailability matching is not purely a generic “bioequivalence study” issue when formulation patents cover:
  • excipient systems,
  • absorption-related features,
  • and tablet characteristics.
• Dosing regimen compliance affects observed exposure variability.

Design-around strategies generally pursued

• Alternative excipient systems or tablet manufacturing processes
• Label-limited dosing regimens intended to avoid method-of-use claim infringement

---

How does Rybelsus compare with Wegovy and Ozempic in patent and market positioning?

Fast answer: Rybelsus is distinct because it is oral and diabetes-labeled. Ozempic is injectable diabetes/CV positioning. Wegovy is obesity-focused. The competitive overlap increases as obesity evidence expands diabetes-on-label use and as payers standardize GLP-1 coverage rules.

Business implication

• Rybelsus competes on:
  • oral convenience,
  • patient preference,
  • and CV-outcomes credibility in diabetes.
• It faces intensified competition where payers steer toward preferred agents within commercial formularies.

---

Key Takeaways

• Rybelsus’ clinical trajectory is anchored in expanding outcomes evidence (CV and renal) and reinforcing long-term glycemic and weight benefit durability.
• Market growth is driven by dose optimization, earlier-line prescribing, and increasing payer confidence in outcomes-labeled incretin therapy.
• Patent and exclusivity timelines are multi-layered, with formulation and method-of-use protections shaping generic entry risk more than a single composition-of-matter date.
• Revenue projections should be scenario-based: growth persists if outcomes and tolerability sustain adherence, while competitive intensity and gross-to-net pressure likely slow growth as class share consolidates and entry pressure rises.

---

FAQs

1. What endpoints in Rybelsus trials are most likely to support label expansion beyond type 2 diabetes?
2. How do dose-escalation and GI tolerability affect Rybelsus persistence and real-world effectiveness?
3. Which patent categories (composition, formulation, method-of-use) most often control generic launch timing for Rybelsus?
4. What factors determine how quickly Rybelsus gains formulary access after a label expansion tied to CV outcomes?
5. How does competition from dual incretin therapies affect expected share and pricing power for Rybelsus?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Rybelsus). U.S. Food and Drug Administration.
2. ClinicalTrials.gov. Studies of oral semaglutide (Rybelsus). U.S. National Library of Medicine.
3. American Diabetes Association. Standards of Care in Diabetes. American Diabetes Association.